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Background: Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction.
Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells
and promote regulatory T-cell (Treg) differentiation. It is presently unknown whether MM cells express IDO1 and
whether IDO1 activity correlates with immune system impairment.
Methods: We investigated IDO1 expression in 25 consecutive patients with symptomatic MM and in 7 patients
with either monoclonal gammopathy of unknown significance (MGUS; n=3) or smoldering MM (SMM; n=4).
IDO1-driven tryptophan breakdown was correlated with the release of hepatocyte growth factor (HGF) and with
the frequency of Treg cells and NY-ESO-1-specific CD8+ T cells.
Results: KYN was increased in 75% of patients with symptomatic MM and correlated with the expansion of CD4
+CD25+FoxP3+ Treg cells and the contraction of NY-ESO-1-specific CD8+ T cells. In vitro, primary MM cells promoted
the differentiation of allogeneic CD4+ T cells into bona fide CD4+CD25hiFoxP3hi Treg cells and suppressed IFN-γ/IL-2
secretion, while preserving IL-4 and IL-10 production. Both Treg expansion and inhibition of Th1 differentiation by
MM cells were reverted, at least in part, by D,L-1-methyl-tryptophan, a chemical inhibitor of IDO. Notably, HGF levels
were higher within the BM microenvironment of patients with IDO+ myeloma disease compared with patients
having IDO- MM. Mechanistically, the antagonism of MET receptor for HGF with SU11274, a MET inhibitor,
prevented HGF-induced AKT phosphorylation in MM cells and translated into reduced IDO protein levels and
functional activity.
Conclusions: These data suggest that IDO1 expression may contribute to immune suppression in patients with
MM and possibly other HGF-producing cancers.Background
The establishment of anti-tumor immunity requires the
interaction of different cell types including, among
others, APC and T cells. Escape from immunosurveil-
lance through immunoselection, also known as immunoe-
diting, and immunosubversion, i.e., active suppression
of the immune response, is a hallmark of cancer [1]. In
this respect, naturally occurring CD4+FoxP3+ regulatory* Correspondence: sergio.rutella@opbg.net
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reproduction in any medium, provided the orT cells (Treg), a T-cell subset frequently over-represented
in cancer-bearing hosts, were shown to suppress tumor-
associated antigen (TAA)-reactive T cells, both in vitro [2]
and in vivo [3]. Indoleamine 2,3-dioxygenase 1 (IDO1) is
a tryptophan-catabolizing enzyme encoded by the IDO1
gene. IDO1 oxidizes tryptophan into N-formylkynurenine,
which is rapidly converted to kynurenine (KYN) by the
action of KYN formamidase [4]. The same reaction can
be catalyzed by tryptophan 2,3-dioxygenase (TDO), a
heme-containing cytosolic enzyme encoded by TDO2
gene and detected at high levels in the liver [5]. In
humans, IDO1 is expressed by a unique subset ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and by a variety of solid tumors, such as colorectal cancer
[9], melanoma [10] and serous ovarian cancer [11]. The
IDO1-driven production of KYN promotes the develop-
ment, stabilization and activation of Treg cells, while sup-
pressing effector T cells, all of which may contribute to
immune system impairment in cancer-bearing individuals
[12]. Recently, a mechanism of tumoral immune resist-
ance centered on tryptophan degradation by TDO has
been described in human tumors, such as melanoma,
hepatocarcinoma, glioma and bladder carcinoma, but not
in leukemia or lymphoma [13,14]. Multiple myeloma
(MM) is a malignant plasma cell (PC) disorder, account-
ing for approximately 1% of neoplastic diseases and
13% of hematological cancers [15], and evolving from a
monoclonal gammopathy of undetermined significance
(MGUS) that progresses to smoldering myeloma (SMM)
and, finally, to symptomatic MM. In recent years, the
introduction of autologous hematopoietic stem cell trans-
plantation (HSCT) and the availability of novel drugs
such as thalidomide, lenalidomide and bortezomib, have
prolonged overall survival [16,17]. Importantly, MM
tumor cells are susceptible to immune recognition in the
form of graft-versus-myeloma effect, as suggested by the
therapeutic efficacy of allogeneic HSCT. Indeed, in 162
cases of newly diagnosed MM, event-free and overall sur-
vival were improved in patients given autologous-
allogeneic HSCT (tandem transplantation) as compared
with patients lacking an HLA-matched sibling donor and
receiving double autologous HSCT [18].
MM is unique in its ability to elude immunosurveil-
lance, as a result of qualitative and/or quantitative ab-
normalities of DC and Treg cells [19], and of enhanced
release of immunoregulatory cytokines by microenviron-
mental cells [20]. For instance, interaction between mye-
loma cells and plasmacytoid DC in MM bone marrow
(BM) triggers the release of known MM-cell growth fac-
tors, including IL-10, IL-6, and MCP-1 or IP10 [21]. Fur-
thermore, BM stromal cells (BMSC) in MM secrete
immunomodulatory and pro-angiogenic molecules, such
as TGF-β, vascular endothelial growth factor, IL-6 and
hepatocyte growth factor (HGF) [22,23]. HGF is a 90-kd
protein that signals through the MET receptor and is
endowed with previously unappreciated effects on the
immune response, as shown both in vitro and in vivo
[24,25]. HGF confers tolerogenic functions to human,
monocyte-derived (Mo)-DC by up-regulating IDO1 ex-
pression and IL-10 secretion [26]. Several MM cell lines
both release and activate HGF by secreting HGF-
activator (HGFA), a factor XIIa-related serine protease
[27]. Importantly, high levels of HGF in serum and BM
fluid of patients with MM predict a dismal prognosis,
with a survival time of 32 and 21 months for patients
with low and high HGF, respectively [23,28]. HGF valueshave been reported to decline after treatment with high-
dose chemotherapy in patients with MM who obtain at
least a partial response [29]. The expression and func-
tion of IDO1 in MM have not been investigated previ-
ously. We provide evidence that KYN are increased in
the peripheral blood (PB) and BM of patients with MM,
in correlation with HGF release, expansion of Treg cells
and shrinkage of NY-ESO-1-specific CD8+ T cells. In
vitro, HGF antagonism with SU11274, a chemical inhibi-
tor of MET, translated into the down-regulation of IDO
protein and functional activity in MM cells.Methods
Abs and reagents
The following tumor cell lines were obtained from
American Type Culture Collection (ATCC; LGC Stan-
dards, Milan, Italy): U266, MOLP-8, RPMI-8226 (human
MM) and U87-MG (human glioma). Primary rat hepato-
cytes were a generous gift of Anna Alisi (OPBG, Rome).
CD138 Microbeads, Human CD4+CD25+ Regulatory
T-Cell Isolation Kit, Monocyte Isolation Kit II, Treg
Suppression Inspector, Mo-DC Differentiation Medium,
Mo-DC Maturation Medium and anti-CD166 (ALCAM
or activated leukocyte cell adhesion molecule) mAb (3A6
clone) were purchased from Miltenyi Biotec (Bergisch
Gladbach, Germany). Anti-human IDO antibodies
(clone 700838), recombinant human IFN-γ, IL-2 and
HGF, as well as ELISA kits for the quantification of
IL-10, TGF-β1, IFN-γ and HGF, were all purchased
from R&D Systems (Oxon, Cambridge, UK). The IDO
chemical inhibitor D,L-1MT, a racemic mixture con-
taining both the levo and the dextro isomer of 1MT,
L-tryptophan, KYN, PMA and ionomycin were obtained
from Sigma Chemicals (St. Louis, MO). 6-Fluoro-3-
[(1E)-2-(3-pyridinyl)ethenyl]-1H-indole (680C91), a select-
ive and potent TDO inhibitor (Tocris Bioscience; Bristol,
UK) was used at 5 μM final concentration [5,14]. STAT3
Inhibitor III (WP1066) was purchased from Santa Cruz
Biotechnology (Milan, Italy). The Human FoxP3 Staining
Set was purchased from eBioscience (San Diego, CA).
FITC-conjugated anti-CD8, FITC-conjugated anti-HLA-
A2, PerCP-conjugated anti-CD19 mAb, PE-conjugated
anti-IL-2 mAb, anti-IL-4 and IL-10 mAb, FITC-
conjugated anti-IFN-γ and anti-IL-17 mAb, FITC-
conjugated anti-CD14 mAb, PE-conjugated anti-CD1a
mAb, Cytofix/Cytoperm™ solution and Golgi Plug
Protein Transport Inhibitor™ were purchased from BD
Biosciences (Mountain View, CA). PE-labeled NY-ESO-
1157-165 pentamers (peptide sequence: SLLMWITQV)
and PE-labeled influenza A58-66 pentamers (peptide se-
quence: GILGFVFTL) were obtained from Pro Immune
(Oxford, UK). Rabbit anti-human antibodies to Akt
(pan) (C67E7) and phosphorylated Akt (Ser473) (D9E)
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Italy). Rabbit anti-human IDO (H-101 clone) and anti-
TDO2 antibodies (N1C1 clone) were purchased from
Santa Cruz Biotechnology and from GeneTex (Irvine,
CA), respectively. Mouse anti-human NY-ESO-1 anti-
bodies were obtained from Life Technologies (Milan,
Italy). The Cell Fixation and Permeabilization Kit was
obtained from Invitrogen (Milan, Italy). Mouse anti-
human GAPDH antibodies were from Millipore (Milan,
Italy). Isotypic control Abs were purchased from BD
Biosciences and eBioscience, as appropriate. SU11274, a
selective MET inhibitor [30], was purchased from Cal-
biochem (La Jolla, CA).Patients’ characteristics
Twenty-five consecutive patients with MM and 7
patients with either MGUS (n=3) or SMM (n=4) partici-
pated into the study (Table 1), which was approved by
the local Ethical Committee (protocol #P/53/CE/2010).
Surplus diagnostic material, i.e., PB and BM samples col-
lected on Hospital admission (disease onset) or during
follow-up visits, was used for the cellular and molecular
studies detailed below, after obtaining patients’ informed
consent. The International Staging System (ISS) was
used to classify myeloma disease [31]. Patients with ISS
stages II and III were grouped together in the analysis,
as they are considered to have higher-risk disease [32].Cell and serum preparation
PB and BM samples collected at simultaneous time-
points were used to isolate PBMC and BMMC by dens-
ity gradient centrifugation on Ficoll-Hypaque (Uppsala,
Sweden). Cells were either used fresh or were stored in
FCS with 10% dimethyl sulfoxide in the vapor phase of
liquid nitrogen until the day of experimental manipula-
tion. Sera obtained by centrifugation of clotted PB and
BM samples at 400g for 20 minutes were rapidly frozen
and stored at −80°C until analysis. Primary MM cells
were purified by positive selection with CD138 microbe-
ads, according to the manufacturer’s instructions. Blood
samples were also obtained by consented age- and sex-
matched healthy blood donors and were used for the
measurement of KYN, tryptophan and HGF as well as
for the enumeration of FoxP3-expressing Treg cells.Expansion of BMSC
BMMC were cultured in RPMI 1640 supplemented with
20% FCS to establish BMSC [33]. The percentage of
BMSC was evaluated after labeling with an anti-CD166
mAb. After 3 weeks in culture, BMSC were either chal-
lenged with 100 IU/ml IFN-γ for 24 hours or were left
untreated. Culture supernatants were collected atbaseline and after IFN-γ provision to measure trypto-
phan levels and KYN production, as will be detailed.
Mixed tumor-cell lymphocyte cultures (MTLC)
CD25+ cells were positively selected from buffy-coat pre-
parations of consenting blood donors with directly con-
jugated anti-CD25 magnetic microbeads (4 μl per 107
cells) [26]. The remaining non-CD25+ fraction was used
to isolate CD4+CD25- cells by positive selection with
anti-CD4 mAb-coated microbeads. Primary MM cells
were cultured under serum-free conditions (10% BIT
HCC-9500; Stem Cell Technologies, Vancouver, BC)
with allogeneic CD4+ T cells in RPMI 1640 medium
[26,34]. After 6 days, cells were harvested to evaluate
cytokine secretion and expression of Treg-associated
markers. In selected wells, IL-2 was provided to the
MTLC at 10 IU/ml. The IDO chemical inhibitor D,L-
1MT was used at 200 μM to assess the role of IDO1 in
the conversion of Treg cells by MM cells.
Cell proliferation tracking
Freshly isolated CD4+ T cells were labeled with CFSE
(2.5 μM; Molecular Probes, Eugene, OR) for 10 minutes
at room temperature. After washings in PBS supplemen-
ted with 3% FCS, cells were used for co-culture experi-
ments. The analysis of CFSE dilution in the proliferating
cell progeny was pursued with the Mod FitW LT 2.0 soft-
ware (Verity Software House Inc., Topsham, ME) [35].
Treg suppression assays
Treg cells emerging from the MTLC were purified as
above described and were co-cultured with allogeneic
CD4+CD25- responder T cells that were pre-loaded with
CFSE. T-cell proliferation was induced with an opti-
mized polyclonal stimulus, consisting of anti-CD2+anti-
CD3+anti-CD28 mAb.
Quantification of Treg cells and NY-ESO-1-specific CD8+ T
cells by flow cytometry
The percentage of CD4+CD25+FoxP3+ Treg cells was
estimated as previously published [26]. Appropriate
fluorochrome-conjugated, isotype-matched mAb helped
establish background fluorescence. Treg cells were iden-
tified and counted as CD4+CD25+FoxP3+ T cells within
the CD4+ T-cell gate. To estimate the frequency of NY-
ESO-1-specific and influenza-specific CD8+ T cells,
PBMC from HLA-A2+ MM patients were first stained
with either NY-ESO-1157-165 pentamers or influenza A58-
66 pentamers for 15 minutes at room temperature and
then with anti-CD8 and anti-CD19 mAb. After washings
with PBS-BSA, the percentage of pentamer-positive cells
was calculated after gating on CD19- lymphoid cells on
a two-color CD8 vs. pentamer plot, to exclude from the
Table 1 Patients’ characteristics
UPN Diagnosis Disease status Light chain isotype Cytogenetics ISS stage Therapy at sampling Clinical status*
1 MM Relapse IgG κ Normal III PDN, Cy Deceased
2 SMM Onset IgG λ t(4;14) N.A. None Alive/SMM
3 MM Stable disease Non secretory Normal I None Alive/PR
4 SMM Onset IgA κ Normal N.A. None Alive/SMM
5 MM Partial response IgG κ Normal I PDN, Thalidomide Alive/PR
6 MM Onset IgG κ Del(13q); t(4;14) I None Deceased
7 MM Onset IgA λ Normal III None Lost at follow-up
8 MM Onset IgG λ Del(13q) I None Alive/PR
9 MM Onset IgD λ Del(13q) I VMPT Alive/CR
10 MGUS – Micromolecular, λ Normal N.A. None Alive/MGUS
11 MM Onset Micromolecular, κ Normal I Prednisone Alive/Stable disease
12 MGUS – IgG κ Normal N.A. None Alive/MGUS
13 MM Onset Micromolecular, κ Normal III Auto-HSCT Alive/CR
14 MM Relapse IgA κ Del(13q) I Prednisone Alive/PD
15 MM Onset NA Normal II None NA
16 MM Partial response IgG λ Normal III PDN Alive/Stable disease
17 MM Relapse IgA λ Normal III PDN Alive/PR
18 SMM Onset IgA κ Normal N.A. None Alive/progressed to MM
19 MM Relapse IgA κ p53 mutation II None Alive/PR
20 MM Stable disease IgG κ Normal I MP Deceased
21 SMM Onset IgG λ Normal N.A. None Alive/SMM
22 MGUS – IgG κ Normal N.A. None Alive/MGUS
23 MM Onset IgG κ t(11;14);14q32 translocation I None Alive
24 MM Onset IgG κ Del(13q); del(17p) II None Alive
25 MM Relapse IgA Del(13q); t(4:14) II None Alive, relapse
26 MM Onset Micromolecular, λ ND III None Alive/PR
27 MM Relapse Non secretory ND I None Alive/VGPR
28 MM Relapse IgA λ Normal I None Alive/VGPR
29 MM Onset IgA κ Del(13q); del(17p) III None Alive/PD
30 MM Onset IgA λ Del(13q); t(4:14) I None Alive/PR
31 MM Relapse IgG κ ND I Prednisone Alive/PD
32 MM Relapse IgG κ ND I None Alive/PR
Patients’ characteristics. Patients’ demographics, disease features, medical therapies and disease status at sampling are shown. Abbreviations: SMM smoldering
multiple myeloma, CR complete remission, PR partial remission, PD progressive disease, VGPR very good partial response, NA not applicable, ND not done, BJ
Bence-Jones proteinuria. PDN prednisone, Cy cyclophosphamide, MP melphalan + prednisone, VMPT bortezomib, melphalan, prednisone and thalidomide
*12 months after inclusion in the study.
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binding of the pentamers to B cells.
Cytokine assays
Cytokine production at the single-cell level was assessed
with mAb directed against IL-2, IL-4, IL-10, IL-17A and
IFN-γ. CD4+ cells were activated for 5 hours with 50 ng/
ml PMA and 1 μg/ml ionomycin, in the presence
of inhibitors of protein transport. For IL-10 detection,
CD4+ cells were stimulated with LPS (1 μg/ml) for 24
hours, washed, fixed, permeabilized and then stained with
pre-titrated amounts of cytokine-specific antibodies. Cyto-
kine levels in patients’ serum or in culture supernatantswere quantitated with commercially available ELISA. The
limits of detection were as follows: 1 pg/ml IL-10; 7 pg/ml
TGF-β1, 15.6 pg/ml IFN-γ, and 40 pg/ml HGF.
Western blotting
Primary CD138+ cells or MM cell lines (6x105) were
centrifuged at 1,200 rpm for 10 minutes and cell pellets
were lysed with RIPA buffer [150 mM NaCl, 1% NP-40,
0,5% sodium deoxycholate, 0,1% SDS, 50 mM Tris–HCl
(pH=8), 1 mM PMSF, 1 mM EGTA, 50 mM NaF, 50
mM Na3VO4 and protease inhibitors (Roche, Milan,
Italy)]. Cell lysates were incubated on ice for 20 minutes
and clarified by centrifugation at 14,000 rpm for
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boiled for 5 minutes at 95°C and analyzed by 12% SDS-
PAGE. Samples were transferred onto nitrocellulose
membrane (Bio-Rad, Milan, Italy). Blots were probed
with primary antibodies at 1:1000 dillution, washed and
developed with horseradish peroxidase-conjugated rabbit
or mouse secondary antibodies (Bio-Rad), as appropri-
ate. The bands were quantified densitometrically using
the ImageJ software (National Institutes of Health,
Bethesda, MD).
Real-time quantitative PCR
Total RNA was obtained from cultured MM cells using
the RNeasy plus kit (Qiagen, Milan, Italy) according
to manufacturer’s instructions. Complementary DNA
(cDNA) was prepared starting from 1 μg of total RNA
using the iScript cDNA Synthesis Kit (Bio-Rad) accord-
ing to the manufacturer’s instructions. Amplifications
were carried out using specific primers (IDO1 gene: for-
ward primer 5’→3’: GGGACACTTTGCTAAAGGCG;
reverse primer 5’→3’: GTCTGATAGCTGGGGGTTGC)
and the iQ SYBRGreen Supermix (Bio-Rad) in a final
volume of 25 μL, starting with a 3-min template de-
naturation step at 95°C followed by 40 cycles of 15s at
95°C and 1 min at 60°C. β-actin was used as housekeep-
ing gene (forward primer 5’→3’: GCCGACAGGATG
CAGAAGGAG; reverse primer 5’→3’: CAGGATGGA
GCCGCCGATC). Standard curves were generated using
a serial dilution of the initial amount of control cDNA
to determine the range of template concentrations, and
showed a good linearity and efficiency for the different
reactions. Melt curves of the reaction products were also
generated to assess the specificity of the measured fluor-
escence. Samples were run in triplicate and the mean of
threshold cycles (Ct) for each specimen was used to ob-
tain the fold-change of gene expression level, using the
following equation: fold change = 2 - (Ct), where Ct =
Ct specific gene-Ct β-actin, and (Ct) = Ct specimen-Ct
control. Calculations were made with the RelQuant
Excel spreadsheet (Bio-Rad).
Differentiation of Mo-DC
Circulating monocytes were isolated with CD14
Microbeads, as already published [33]. Monocytes were
routinely >97% pure, as evaluated by FACS analysis.
Cells were cultured for 7 days in GM-CSF/IL-4-contain-
ing medium, followed by 3 days of maturation in TNF-
α-containing medium.
Immunofluorescence analysis
Labeled cells were run through a FACS CantoW flow cyt-
ometer (BD Biosciences) with standard equipment. A
minimum of 20,000 events was collected and acquiredin list mode using the FACS DivaW software package
(BD Biosciences).
IDO1 activity
Tryptophan and KYN levels were measured with
reverse-phase HPLC. Briefly, sample aliquots were
deproteinized with 0.3 M HClO4. Supernatants were
spiked with 50 μM 3-L-nitrotyrosine and analyzed using
a ReproSil-Pur C18-AQ RP-HPLC column (Dr. Maisch
GmbH, Ammerbuch-Entringen, Germany), using a
double-pump HPLC apparatus from Jasco (Tokyo, Japan)
equipped with spectrophotometric and fluorescence
detectors. The chromatographic peaks were detected by
recording UV absorbance at 360 nm and emission fluor-
escence at 366 nm, after excitation at 286 nm. The elu-
tion solvent was as follows: 2.7% CH3CN in 15 mM
acetate buffer, pH 4.00 (both HPLC-grade; Fluka, Milan,
Italy). The Borwin 1.5 and MS Excel software packages
were used for instrument set-up and peak quantifica-
tion. The concentration of components was calculated
according to peak heights and was compared with both
3-nitro-L-tyrosine as internal standard and with reference
curves constructed with L-tryptophan and KYN.
Statistical methods
The approximation of data distribution to normality was
tested preliminarily using statistics for kurtosis and sym-
metry. Data were presented as median and inter-quartile
range and comparisons were performed with the Mann–
Whitney U test for paired or unpaired data, or with the
Kruskal-Wallis test with Bonferroni’s correction for mul-
tiple comparisons, as appropriate. The criterion for stat-
istical significance was defined as a p value ≤ 0.05.
Results
IDO1 is functional and is mainly expressed by the
malignant PC
In mice, most of the KYN formed through the action of
IDO is pooled in both plasma and tissues [4]. Based on
this observation, we measured tryptophan and KYN
both in serum and in BM fluid collected from a cohort
of 25 patients with newly diagnosed or relapsed MM,
and in 7 patients with either SMM (n=4) or MGUS
(n=3) as controls. In the overall population of patients
with PC dyscrasia, KYN were higher both in the PB
(2.92 μM/L, range 1.0-7.1) and in the BM (2.0 μM/L,
range 0.45-9.57) as compared with age/sex-matched
healthy controls (1.80 μM/L, range 1.11-2.65, and 1.5
μM/L, range 0.6-2.21, in PB [p<0.0001] and BM
[p=0.0141], respectively), suggesting in vivo activation of
IDO1. When MM patients were arbitrarily dichotomized
based on serum KYN (lower or greater than the median
in healthy controls, i.e., 1.8 μM), 19 out of 25 patients
(75%) could be assigned to the KYNhi MM group. KYN
Bonanno et al. Journal of Translational Medicine 2012, 10:247 Page 6 of 17
http://www.translational-medicine.com/content/10/1/247levels were also augmented in the PB and BM of patients
with MGUS and SMM and no statistically significant
differences in KYN release were recorded when compar-
ing these patient groups (data not shown). As the com-
posite results in Figure 1A clearly show, KYN were
significantly more represented in the BM microenviron-
ment of patients assigned to ISS stage II/III compared
with those having less advanced disease. Furthermore,
tryptophan concentrations both in PB and in BM were
lower in MM patients with ISS stage II-III disease com-
pared with MM patients with ISS stage I disease and
with healthy controls (Figure 1A).
Malignant PC were magnetically isolated in 17 MM
patients with sufficient amounts of surplus diagnostic
material, and the expression of IDO protein wasA 
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Figure 2A, IFN-γ challenge induced IDO protein in
CD166+ BMSC from MM patients. KYN were not
detected in unstimulated cultures (Figure 2B). Conversely,
IFN-γ induced robust KYN production by MM BMSC
that was associated with tryptophan consumption
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type upon T-cell activation induced by alloantigens. As
shown in Figure 2C, FoxP3lo and FoxP3hi cell populations
were clearly distinguishable after flow cytometric analysis.
The frequency of CD4+CD25+FoxP3low T cells in the
MLR cultures was significantly expanded irrespective of
the presence of supernatants derived from MM BMSC
and likely reflected T-cell activation in response to HLA-B
A
+IFN-  No IFN-  
MM MM Fibr Fibr
0.0
17.5
35.0
52.5
70.0
*
*
+IFN-
No IFN-
K
yn
u
re
n
in
e 
(
M
)
MM MM Fibr Fibr
0
20
40
60
80
100
*
+IFN-
No IFN-
T
ry
p
to
p
h
an
 (
M
)
Figure 2 IDO1 activity in MM BMSC. Panel A: BMSC were generated as p
100 IU/ml IFN-γ for 24 hours. BMSC were fixed, permeabilized and stained
out of 5 with similar results is shown. Panel B: BMSC from 5 representative
either left untreated (black dots) or activated with 100 IU/ml IFN-γ for 24 h
supernatants. Comparisons between untreated and IFN-γ-stimulated sampl
rank test. *p<0.01 compared with untreated samples. Panel C: Supernatants
allogeneic naïve CD4+ T cells and third-party monocytes (at a fixed 1:3 ratio
After 6 days, cells were harvested and labeled with anti-FoxP3 and anti-CD
A representative experiment out of 3 with similar results is shown. Markers
Rectangular gates were set to include CD4+CD25hiFoxP3hi T cells.disparate stimulator cells. Interestingly, the provision of
tryptophan-depleted and KYN-enriched supernatants
from MM BMSC translated into a significant increase of
CD4+CD25+FoxP3hi Treg cells (Figure 2C). The addition
of excess tryptophan to the MLR did not limit the expan-
sion of either FoxP3lo or FoxP3hi Treg cells (Figure 2C),
suggesting that the increase of Treg cells in the cultures
was not merely due to tryptophan starvation but rather it
resulted from increased KYN production. Collectively,
these data indicated that, in the absence of pro-
inflammatory stimuli such as IFN-γ, BMSC are unlikely
to account for IDO1 expression/activity in patients with
MM. In line with this assumption, we were unable to de-
tect IFN-γ in the BM fluid of patients with MM (data not
shown). A previous study also showed no constitutive
IDO activity in BMSC from 5 patients with MM [36].
IDO1 activity in MM correlates with the expansion of Treg
cells and with the contraction of NY-ESO-1-specific CD8+
T cells
We also asked whether IDO1 activity correlates with
in vivo expansion of potentially immune-suppressiveC CD4 alone 
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reviously detailed [33] and were either left untreated or activated with
with anti-IDO and anti-CD166 mAb. One representative experiment
patients with MM and skin fibroblasts from 6 healthy subjects were
ours (red dots) before measuring KYN and tryptophan level in culture
es were performed with the Wilcoxon matched-paired signed
of BMSC cultures were transferred (20% v/v) to an MLR containing
). IL-2 was provided to the cultures as a Treg growth factor.
25 mAb to monitor the acquisition of a regulatory phenotype.
were set according to the proper isotypic control (not shown).
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http://www.translational-medicine.com/content/10/1/247Treg cells. The gating strategy that we used to enumer-
ate Treg cells in patients’ PB and BM is illustrated in
Additional file 1. As shown in Figure 3A, the frequency
of bona fide Treg cells in the PB was significantly higher
in patients with higher stage MM compared with
patients with ISS stage I disease and with healthy con-
trols. The increase of Treg cells also within BMMC of
patients with ISS stage III disease (median 6.2%, range
4.40-14.6) compared with stage II disease (median 9.3%,A B
D
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Figure 3 IDO activity correlates with expanded Treg cells and with di
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ranges. Comparisons between MM patients and healthy controls were perf
correction for multiple comparisons. Panel B: Patients with MM were arbitr
lower than the median in healthy controls (1.8 μM), respectively. The frequ
with the Kruskal-Wallis test for unpaired determinations. Bars illustrate med
circulating Treg cells was correlated with IDO protein levels, as measured b
with MM. r2=0.4332; p=0.0041. Panel D: The expression of HLA-A2 on PB le
anti-HLA-A2 mAb in 22 MM patients whose malignant PC expressed NY-ES
whereas 6 were HLA-A2-. PBMC from the 16 HLA-A2+ MM patients were st
Methods. The frequency of influenza-specific CD8+ T cells was measured in
experiment is shown. Panel E: The frequency of NY-ESO-1-specific CD8+ T c
patients. The very low percentage of NY-ESO-1-specific CD8+ T cells in the
staining. Panel F: The frequency of Treg cells in the 16 HLA-A2+ MM patien
and inter-quartile ranges.range 4.6-14.1), stage I disease (median 4.15%, range 1.0-
7.6%) and with healthy donors (median 3.1%, range 2.3-
4.0) suggested that Treg accumulation in the MM
microenvironment may be one additional mechanism
through which anti-myeloma immunity is restrained.
The frequency of circulating Treg cells was superimpos-
able when comparing patients having MGUS or SMM
with those suffering from symptomatic MM (data
not shown).C
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http://www.translational-medicine.com/content/10/1/247Interestingly, CD4+CD25+FoxP3+ Treg cells were more
abundant in the PB of MM patients with heightened
KYN levels (Figure 3B). The frequency of Treg cells also
correlated with IDO protein levels, as determined by
Western blotting (r2=0.4332, p=0.0041; Figure 3C). To
get insights into the potential in vivo relevance of the
above findings, we evaluated the frequency of myeloma-
reactive, NY-ESO-1-specific CD8+ T cells in a subgroup
of 16 HLA-A2+NY-ESO-1+ MM patients, 10 of whom
could be classified as KYNhi based on serum KYN
(Figure 1A). The expression of NY-ESO-1 was tested
with Western blotting in this subgroup of patients and is
shown in Additional file 2A. Additional six HLA-A2-
MM patients served as negative control for pentamer
staining. In the HLA-A2+ patients, the frequency of
influenza-specific CD8+ T cells was measured together
with that of NY-ESO-1-specific CD8+ T cells to rule out
immune exhaustion (Figure 3D). Overall, compared with
the KYNlo MM patients, HLA-A2+KYNhi MM patients
had fewer NY-ESO-1-specific CD8+ T cells (Figure 3E),
but higher frequencies of Treg cells (Figure 3F), indicat-
ing that, at least in a subset of MM patients, IDO1 activ-
ity may impact on anti-myeloma immunity through
effects that include both the expansion of Treg cells and
the contraction of myeloma-specific effector T cells. As
already shown in the whole cohort of MM patients
(Figure 3A), also in this subgroup of 10 KYNhiHLA-A2+
MM patients Treg cells were significantly more repre-
sented than in both KYNloHLA-A2+ MM patients and
healthy controls (Figure 3F).
Myeloma cells lead to the differentiation of Treg cells
in vitro through an IDO-dependent mechanism
To test the hypothesis that IDO1-expressing myeloma
cells sustain the amplification of Treg cells, allogeneic
naïve CD4+ T cells were challenged in vitro with
myeloma cells in a MTLC. The CD4+ T cells were pre-
loaded with the fluorescent dye CFSE to track their pro-
liferation. As evaluated through the combined staining
with CFSE and anti-FoxP3 mAb (Figure 4A-B), IDO+
myeloma cells induced an expansion of the overall Treg
population. These effects were inhibited, albeit not com-
pletely, by the provision of D,L-1MT to the co-cultures.
To assess whether proliferating myeloma cells competed
for tryptophan, leading to its relative depletion inde-
pendent of IDO, MM cells were loaded with CFSE and
cultured for 72 hours to track cell proliferation. As
shown in Additional file 2B, MM cells had minimal pro-
liferative activity when maintained with complete
medium in the absence of exogenous growth factors.
The MM-induced Treg cells were capable of constrain-
ing the proliferation of allogeneic CD4+ T cells induced
by polyclonal stimulation with a cocktail of anti-CD2/
CD3/CD28 mAb, indicating that they were functional(Figure 4C). The CD4+ T cells emerging from the MTLC
were also activated with PMA and ionomycin and then
assayed for intracellular cytokines assigned to the Th1,
Th2 and Th17 lineage. A representative control experi-
ment with commercially available Th1/Th2-polarized T
cells is depicted in Additional file 3A. Figure 4D shows
the results of 3 experiments where IDO-expressing MM
cells inhibited the development of IFN-γ/IL-2-producing
T cells in vitro. Conversely, IL-10, IL-17 and IL-4-
expressing CD4+ T cells were unchanged after T-cell co-
culture with MM cells. Interestingly, D,L-1MT partially
reverted the diminished T-cell expression of IFN-γ and
IL-2 in response to MM cells, and slightly increased
IL-10 production at the single-cell level (Figure 4D).
Figure 4E illustrates a representative experiment aimed
at measuring IL-2 and IFN-γ production under the dif-
ferent culture conditions here established.
IDO1 activity in MM patients correlates with the release
of HGF but not other immune-suppressive cytokines
We next focused our studies on candidate cytokine stim-
uli that may be responsible for IDO1 induction in MM.
In this respect, both TGF-β and IL-10 are known to
modulate IDO1 and may be expressed by the myeloma
cells during progressive disease [37]. To this end, TGF-β
and IL-10 levels were measured in a subgroup of 19
MM patients (Additional file 3B). Although both IL-10
and TGF-β were increased in some patients, both in the
PB and BM, there was no correlation between IL-10/
TGF-β release and serum KYN (data not shown). We
subsequently quantitated HGF production both in PB
and in BM fluid and showed that HGF was dramatically
increased in patients with MM compared with those
having MGUS or SMM, being particularly elevated
in the immune-suppressive BM microenvironment
(Figure 5A-B). Furthermore, HGF levels were higher in
patients with ISS stage II/III disease compared with
those having ISS stage I MM (Figure 5C-D), suggesting
that the magnitude of HGF release reflects disease bur-
den. Also, HGFA, whose presence is a pre-requisite for
HGF activation in vivo [27], was higher in patients’
PB and BM fluid compared with healthy controls
(Figure 5E). When attempting to correlate HGF levels
with KYN production, we found that HGF was higher in
the BM microenvironment of patients with KYNhi MM
compared with those having KYNlo MM (Figure 5F).
Also, serum HGF was not significantly different in the
KYNlo MM patients than in healthy controls. However,
it should be emphasized that HGF levels overlapped in
KYNlo patients and in a subgroup of 8 out of 19 (42%)
KYNhi patients. Conversely, HGF levels were dramatic-
ally increased in the remaining 11 KYNhi patients when
compared with KYNlo MM and with healthy controls.
As shown in Figure 5G, disease burden, HGF release as
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Figure 4 IDO+ myeloma cells induce a Tr1/Th2 profile and suppress Th1 cytokines in allogeneic CD4+ T cells. Panels A and B: Highly
pure CD138+ PC from patients with MM were used for MLTC, as detailed in Materials and Methods. The allogeneic CD4+CD25- T cells were
pre-loaded with CFSE to monitor cell division. Exogenous IL-2 was provided to the MLTC at 100 IU/ml (final concentration). In selected wells,
D,L-1MT was added at 200 μM (final concentration) to inhibit IDO activity. After 6 days in culture, cells were harvested and labeled with
anti-FoxP3 and anti-CD25 mAb. Quadrant markers were set according to the proper isotypic control. A representative experiment is shown in
panel A, whereas results are summarized in panel B. Panel C: CFSE dilution in responder CD4+CD25- T cells was expressed in terms of mean
fluorescence intensity of the dividing cell population (MFI). The bars depict the median and interquartile range recorded in 3 independent
experiments performed in duplicate. The black column denotes T-cell cultures that were stimulated with anti-CD2+anti-CD3+anti-CD28 mAb in
the absence of MM-induced Treg cells. Panel D: MM cells from KYNhi patients were seeded in a MTLC as above detailed. After 6 days in culture,
T cells were collected and used for intracellular cytokine staining. The percentage of IL-2, and IFN-γ-expressing T cells shown in panel E is
representative of 3 independent experiments. Quadrant markers were set according to the proper isotypic control.
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http://www.translational-medicine.com/content/10/1/247well as KYN and tryptophan levels were evaluated seri-
ally in 1 patient with MM, both before (disease onset)
and after treatment (T1 and T2 = 6 months and 1 year,
respectively, after combination chemotherapy with bor-
tezomib, melphalan and prednisone). The percentage of
malignant PC and serum M-component progressively
declined in correlation with lowered HGF and KYN re-
lease. Moreover, the percentage of Treg cells diminished
after treatment compared with baseline. Collectively,
these data suggest that high HGF production in MM
may correlate with IDO1 activity and with disease bur-
den. Finally, we aimed at establishing a mechanistic link
between HGF stimulation and IDO expression by MM
cells. Preliminarily, we confirmed our previous findings
that HGF potently induces IDO protein in mature,CD14-CD1a+ Mo-DC (Figure 6A-B) [26]. Prompted by
technical limitations in the collection of high numbers
of primary PC from MM patients, we treated U266 and
MOLP-8 MM cells with exogenous HGF and then ana-
lyzed IDO expression at mRNA and protein level, as well
as KYN release in culture supernatants [38]. As shown
in Figure 6C, mRNA levels for IDO1 were unaffected by
HGF, at variance with those detected in IFN-γ-
stimulated MM cells. Treatment with HGF resulted in
enhanced phosphorylation of AKT, as well as increased
IDO1 expression and enzyme activity in MOLP-8 cells
(Figure 6D). Of interest, 1MT reverted the heightened
KYN/tryptophan ratio measured in supernatants of
HGF-stimulated MOLP-8 cells, indicating that KYN pro-
duction could be ascribed to IDO1 activity (Figure 6E).
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Figure 5 HGF release correlates with disease burden and with IDO activity in patients with MM. HGF levels were measured with ELISA
both in PB and BM fluid of patients with MGUS, SMM and symptomatic MM at different ISS stages (panels A-D). HGF levels in patients and
controls were compared with the Kruskal-Wallis test for unpaired determinations with Dunns correction for multiple comparisons. Bars depict
median values and inter-quartile ranges. Panel E: HGFA in PB and BM fluid was measured in patients with MM using commercially available ELISA
kits. Comparisons were performed with the Kruskal-Wallis test for unpaired determinations with Dunns correction for multiple comparisons.
Panel F: HGF levels in the BM microenvironment were correlated with IDO activity, as expressed in terms of KYN release into the systemic
circulation. When MM patients were dichotomized based on KYN levels (<1.8 μM or >1.8 μM), KYNhi patients released significantly higher levels of
HGF compared with KYNlo patients. Comparisons were performed with the Kruskal-Wallis test for unpaired determinations with Dunns correction
for multiple comparisons. Panel G: Disease burden, HGF release, KYN and tryptophan levels were measured in 1 patient with MM, both before
(disease onset) and after treatment (T1 and T2 = 6 months and 1 year, respectively, after chemotherapy with bortezomib, melphalan and
prednisone). The percentage of malignant PC as well as serum levels of M-component progressively declined, in correlation with serum and BM
HGF, and with KYN.
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http://www.translational-medicine.com/content/10/1/247Figure 6D also illustrates that pre-treatment of U266
and MOLP-8 MM cells with SU11274, a MET inhibitor,
antagonized both baseline and HGF-stimulated activa-
tion of AKT. The STAT3 pathway has been implicated
in immune suppressive circuits [39]. In addition, HGF
can induce STAT3 phosphorylation and STAT3, in turn,
interacts with MET, both directly and indirectly [40]. As
shown in Figure 7A, WP1066, a potent STAT3 inhibitor,
down-regulated STAT3 phosphorylation as well as IDO
protein expression in MOLP-8 MM cells, but not in
U266 MM cells, suggesting that HGF may be implicated
in IDO regulation through multiple signaling pathways,
at least in some MM cases. Finally, we focused our stud-
ies on TDO expression and activity in MM cells.Figure 7B shows that TDO protein levels were low in
MM cells compared with glioma cells and primary rat
hepatocytes. At variance with 1MT, 680C91, a selective
and potent TDO inhibitor, failed to revert the increased
KYN/tryptophan ratio in supernatants of MM cells
(Figure 7C), suggesting that KYN production by MM
cells was mainly accounted for by IDO1 activity.
Discussion
MM is a malignant PC disorder with a unique ability to
subvert and/or escape immune responses. The interac-
tions of MM cells with the BM microenvironment, ei-
ther directly through inter-cellular adhesion or indirectly
through the effects of growth factors, activate a variety
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Figure 6 HGF modulates IDO in MM cell lines. Panel A: Mo-DC were differentiated from circulating monocytes of healthy donors with
GM-CSF+IL-4 (7 days; immature Mo-DC or iDC) and then matured with TNF-α (2 additional days; mature DC or mDC), as already published [26].
Mature Mo-DC were routinely CD14dim/negCD1a+, as determined by FACS analysis. Panel B: Mo-DC differentiated in the presence of exogenous
HGF at 20 ng/ml and then matured with TNF-α up-regulated IDO protein. Panel C: U266 and MOLP-8 MM cells were stimulated with either IFN-γ
or HGF for 24h. Messenger RNA levels for IDO were measured with quantitative RT-PCR relative to β-actin. Bars depict mean and SD recorded
in 3 independent experiments. Panel D: U266 and MOLP-8 MM cells were stimulated with 20 ng/ml HGF for 24 hours. Cell lysates were
immunoblotted with phosphorylation-specific antibodies against AKT (Ser473) [62]. SU11274, a selective MET inhibitor, was provided at 100 nM
to the cultures. IFN-γ at 100 IU/ml was used as a prototypical inducer of IDO. Panel E: Tryptophan and KYN concentrations were measured in
supernatants of U266 and MOLP-8 MM cells that were stimulated with 20 ng/ml HGF either in the presence or absence of 1MT. Results are
representative of 3 independent experiments run in duplicate.
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http://www.translational-medicine.com/content/10/1/247of signaling cascades [22]. In this respect, HGF released
by both MM cells and BMSC is rapidly emerging as a
potential target for treatment both in MM and in B-cell
lymphomas [41]. Importantly, MM should be amenable
to therapies aimed at restoring anti-tumor immunity,
since MM cells are sensitive to immune attack in the
form of graft-versus-myeloma effect [42]. A large major-
ity of human tumors, including prostate, pancreatic and
colorectal carcinomas, express IDO in a constitutive
manner [43]. IFN-γ is a prototypical IDO1-inducing
cytokine in solid tumor cell lines, but not in cells of ei-
ther lymphoid or myeloid origin, such as MM [44] and
myeloid leukemia cells [45,46]. Our study evaluated the
expression and function of IDO1 in human MM sam-
ples. In approximately 75% of unselected patients with
symptomatic MM, IDO1 activation was reflected by the
increase of serum KYN, the end-product of tryptophanbreakdown by IDO. KYN levels were particularly ele-
vated within the immune suppressive BM microenviron-
ment of patients with ISS stage II/III myeloma disease.
In the majority of MM patients, malignant PC cells were
identified as a major source of IDO1 expression by
Western blotting and flow cytometry. In agreement with
previously published results [36], patient-derived BMSC
were exquisitely sensitive to IFN-γ challenge, as shown
by the robust KYN production and concomitant trypto-
phan depletion in culture supernatants. This observation
has two potential implications. First, IFN-γ may not be
the primary cytokine stimulus driving IDO expression in
MM. Second, the IDO- BMSC may start expressing IDO
when exposed to an inflammatory milieu enriched in
IFN-γ, implying that the immune resistance mechanisms
centered on IDO could be exploited in vivo both by the
myeloma cells and by microenvironmental cell types,
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http://www.translational-medicine.com/content/10/1/247such as BMSC. Notably, IFN-γ-challenged BMSC iso-
lated from 5 patients with MM induced IDO-dependent
tryptophan deprivation, leading to MM cell apoptosis
and inhibited in vitro growth [36]. It is also conceivable
that microenvironmental cell types other than malignant
PC may be endowed with IDO activity. In this respect,
BM-resident CD14+ monocytes and BDCA-4+ plasmacy-
toid DC from MM patients express readily detectable
levels of IDO protein (Rutella S, unpublished observa-
tions, 2012). It remains to be determined whether other
accessory cells partake in IDO-driven immune suppres-
sive circuits in MM. In this respect, activation of the
KYN pathway has been reported in patients with auto-
immune diseases, such as rheumatoid arthritis, systemic
lupus erythematosus and systemic sclerosis, likely as a
result of IDO1 expression by non-hematopoietic cell
types, such as fibroblasts, epithelial cells and vascular
endothelial cells [47,48].
Conflicting reports have been published on the fre-
quency of FoxP3-expressing Treg cells in patients with
MGUS and MM, with studies showing either a decrease
[49] or an increase of Treg cells [50]. In our cohort ofMM patients, Treg cells were over-represented both in
PB and BM, suggesting that Treg cells may mediate im-
mune escape also in the BM microenvironment. Import-
antly, the in vivo expansion of bona fide Treg cells was
more pronounced in patients with ISS stage II/III disease
and correlated with both IDO1 expression in BM PC
and enzyme activity, i.e., serum KYN levels. The NY-
ESO-1 cancer/testis antigen is frequently over-expressed
in MM, being a potential target for immunotherapy [51].
The percentage of NY-ESO-1-specific CD8+ T cells was
significantly lower in KYNhi MM patients and was nega-
tively correlated with Treg-cell expansion, implying that
IDO1 activity may affect the anti-myeloma immune re-
sponse either directly or indirectly, through the Treg
compartment. Co-cultures of allogeneic T cells with
IDO-expressing MM cells indicated that Treg-cell ex-
pansion was mediated by IDO, as it could be inhibited,
albeit not completely, by the provision of the racemic
mixture D,L-1MT. We consistently observed a ~50% re-
duction of Treg conversion by the IDO+ myeloma cells,
both in the presence of D,L-1MT and in the presence of
the racemer L-1MT (data not shown). This may indicate
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in addition to IDO1 expression, are operational or that
1MT-mediated inhibition of IDO1 was itself incomplete.
The FoxP3-expressing Treg cells that emerged from the
MM/T-cell co-cultures restrained allogeneic T-cell pro-
liferation, suggesting that they were functional. In vitro,
MM cells favored the differentiation of both FoxP3lo and
FoxP3hi Treg cells. It has been reported that ‘naive’ Treg
cells are characterized by their low levels of intracellular
FoxP3 [52], whereas ‘effector’ Treg cells express a Fox-
P3hi phenotype [53]. It is tempting to speculate that MM
cells may deliver signals for initiating the expansion of
both naïve Treg cells in a resting state and activated
functionally differentiated effector Treg cells [54]. Fur-
thermore, CD4+ T cells primed with IDO+ MM cells
acquired a IFN-γdimIL-2dimIL-4+IL-10+ cytokine secre-
tion profile, consistent with type 1 Treg cells (Tr1)/Th2
cells. Other reports have also attributed to MM cell
lines, such as U266 and RPMI-8226 cells, and to fresh
MM cells the ability to down-regulate IFN-γ release by
both un-activated and activated T lymphocytes [55].
Also, previous studies documented the capacity of mye-
loma cells to induce Tr1/Th2 cytokine production by T
cells [56]. In our co-culture system, 1MT partially
reverted the inhibition of Th1 cytokine production, sug-
gesting that IDO-expressing MM cells may impinge both
on Treg responses and on the Th1/Th2 balance [57].
Our interest in HGF as a candidate stimulus driving
IDO1 expression in MM stems from studies underpin-
ning the role of HGF in myeloma pathogenesis and from
our previous report on the ability of HGF to induce
IDO1 in human DC [26]. In our cohort of MM patients,
HGF was over-expressed both in PB and BM, being par-
ticularly elevated in patients with ISS stage II/III MM. In
addition, serial measurements of disease burden, HGF
levels and KYN-to-tryptophan ratio in 1 MM patient
showed that IDO1 activity decreased concomitantly with
the reduction of both HGF release and PC infiltration in
the BM microenvironment. It should be noted that, al-
though HGF levels were collectively higher in KYNhi
compared with KYNlo MM patients, a subgroup of 11
KYNhi MM patients were characterized by remarkably
heightened HGF levels. However, their clinical and bio-
logical characteristics were not significantly different
from those of the other MM patients herein analyzed,
including the prevalence of unfavorable cytogenetics,
such as del(13q) and t(4;14) [58], the magnitude of BM
infiltration with malignant PC at diagnosis or the ISS
stage. The small number of patients, however, precluded
any sensible conclusion on the impact of high IDO ac-
tivity on overall survival, an issue that could be
addressed by studies with larger cohorts of MM patients.
Recently, a tumoral immune resistance mechanism cen-
tered on TDO has been described [5,14]. In our study,MM cell lines expressed low levels of TDO compared
with glioma cell lines and with primary rat hepatocytes.
The provision of a selective TDO inhibitor to MM cells
did not affect KYN production nor tryptophan con-
sumption, suggesting that TDO is unlikely to play a
major role in tryptophan breakdown by MM cells. The
HGF/MET pathway is an emerging target for the treat-
ment of MM, B-cell lymphomas and solid tumors
[59,60]. MET signaling is mainly mediated by the ERK-
MAPK and PI3K-AKT pathways. However, several types
of cooperation and crosstalk between MET and other
signaling systems, such as TGF-β, WNT and others,
have been unveiled in human cancer [61,62]. We con-
firmed that HGF is a powerful inducer of IDO in Mo-
DC [26,63] and extended this observation to show that
HGF may be implicated in the regulation of IDO expres-
sion also in MM cells. In support of this statement, the
provision of a MET kinase inhibitor to both U266 and
MOLP-8 MM cells translated into a remarkable down-
regulation of IDO protein, in correlation with inhibited
AKT phosphorylation. It should be pointed out that
other signaling pathways, including those centered on
STAT3 [64], may be operational in MM cells. This is
supported by our observation that WP1066, a potent
STAT3 inhibitor, abrogated IDO expression in MOLP-8
cells, either constitutive or induced by IFN-γ. Theoretic-
ally, the interaction between HGF and its receptor can
be blocked by antagonists of either HGF or MET [65].
NK4, a truncated splice variant of HGF corresponding
to the α chain of HGF, competitively antagonizes HGF
and inhibits MM growth both in vitro and in vivo [66].
Intriguingly, NK4 in combination with DC vaccination
inhibited the growth of experimental solid tumors,
promoted tumor antigen-specific secretion of IFN-γ by
CD8+ T cells and elicited MHC class I-restricted CTL
activity against the parental tumor cells [67]. This study
strongly suggests that HGF antagonism may break im-
mune tolerance in tumor-bearing hosts.
Conclusions
In conclusion, we provide evidence that IDO1 is
expressed and has functional activity in the majority of
patients with MM. Ex vivo studies point to HGF as one
cytokine stimulus mediating IDO1 induction in MM. It
remains to be determined whether targeting the HGF/
MET axis in MM and other HGF-expressing cancers will
interfere with the tumor-induced immune dysfunction
through the inhibition of IDO activity.
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